Pemvidutide(Pemvidutide) - 药物靶点：GCGR x GLP-1R_在研适应症：非酒精性脂肪性肝炎，肥胖，2型糖尿病_专利_临床

概要

基本信息

药物类型

合成多肽

别名

ALT-801、ALT-801- Altimmune、MD-1373

+ [2]

靶点

GCGR x GLP-1R

作用方式

激动剂

作用机制

GCGR激动剂(胰高血糖素受体激动剂)、GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

消化系统疾病内分泌与代谢疾病

在研适应症

非酒精性脂肪性肝炎肥胖2型糖尿病

非在研适应症-

原研机构-

在研机构

Altimmune, Inc.

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评快速通道 (美国)

登录后查看时间轴

结构/序列

Sequence Code 28085928

来源: *****

关联

11

项与 Pemvidutide 相关的临床试验

NCT05989711

/ Active, not recruiting临床2期

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)

Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.

开始日期2023-07-27

申办/合作机构

Altimmune, Inc.

NCT05295875

/ Completed临床2期

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)

This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.

开始日期2022-03-31

申办/合作机构

Altimmune, Inc.

NCT05292911

/ Completed临床1期

A 12-Week Extension Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

This extension study will assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (NAFLD).

开始日期2022-03-09

申办/合作机构

Altimmune, Inc.

100 项与 Pemvidutide 相关的临床结果

登录后查看更多信息

100 项与 Pemvidutide 相关的转化医学

登录后查看更多信息

100 项与 Pemvidutide 相关的专利（医药）

登录后查看更多信息

5

项与 Pemvidutide 相关的文献（医药）

2025-01-01·JOURNAL OF HEPATOLOGY

Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study

Article

作者: Browne, Sarah K ; Harrison, Stephen A ; Gutierrez, Julio A ; Roberts, M Scot ; Suschak, John J ; Harris, M Scott ; Yang, Jay ; Tomah, Shaheen

BACKGROUND & AIMS:

This was a randomized, double-blind, placebo-controlled study to assess the effects of pemvidutide, a glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist, on liver fat content (LFC) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).

METHODS:

Patients with a BMI ≥28.0 kg/m² and LFC ≥10% by magnetic resonance imaging-proton density fat fraction were randomized 1:1:1:1 to pemvidutide at 1.2 mg, 1.8 mg, or 2.4 mg, or placebo administered subcutaneously once weekly for 12 weeks. Participants were stratified according to a diagnosis of type 2 diabetes mellitus. The primary efficacy endpoint was relative reduction (%) from baseline in LFC after 12 weeks of treatment.

RESULTS:

Ninety-four patients were randomized and dosed. Median baseline BMI and LFC across the study population were 36.2 kg/m² and 20.6%; 29% of patients had type 2 diabetes mellitus. At week 12, relative reductions in LFC from baseline were 46.6% (95% CI -63.7 to -29.6), 68.5% (95% CI -84.4 to -52.5), and 57.1% (95% CI -76.1 to -38.1) for the pemvidutide 1.2 mg, 1.8 mg, and 2.4 mg groups, respectively, vs. 4.4% (95% CI -20.2 to 11.3) for the placebo group (p <0.001 vs. placebo, all treatment groups), with 94.4% and 72.2% of patients achieving 30% and 50% reductions in LFC and 55.6% achieving normalization (≤5% LFC) at the 1.8 mg dose. Maximal responses for weight loss (-4.3%; p <0.001), alanine aminotransferase (-13.8 IU/L; p = 0.029), and corrected cT1 (-75.9 ms; p = 0.002) were all observed at the 1.8 mg dose. Pemvidutide was well-tolerated at all doses with no severe or serious adverse events.

CONCLUSIONS:

In patients with MASLD, weekly pemvidutide treatment yielded significant reductions in LFC, markers of hepatic inflammation, and body weight compared to placebo.

IMPACT AND IMPLICATIONS:

Metabolic dysfunction-associated steatotic liver disease, and its progressive form steatohepatitis, are strongly associated with overweight/obesity and it is believed that the excess liver fat associated with obesity is an important driver of these diseases. Glucagon-like peptide-1 receptor (GLP-1R) agonists elicit weight loss through centrally and peripherally mediated effects on appetite. Unlike GLP-1R agonists, glucagon receptor agonists act directly on the liver to stimulate fatty acid oxidation and inhibit lipogenesis, potentially providing a more potent mechanism for liver fat content reduction than weight loss alone. This study demonstrated the ability of once-weekly treatment with pemvidutide, a dual GLP-1R/glucagon receptor agonist, to significantly reduce liver fat content, hepatic inflammatory activity, and body weight, suggesting that pemvidutide may be an effective treatment for both metabolic dysfunction-associated steatohepatitis and obesity.

CLINICAL TRIAL NUMBER:

NCT05006885.

2024-09-01·Indian journal of endocrinology and metabolism

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article

Review

作者: Kalra, Sanjay ; Kalhan, Atul ; Sidrak, Wael R.

Abstract:

Obesity is a heterogeneous, complex, and chronic disease that has a detrimental impact on disability-adjusted life years across the globe. Recent advancements in our understanding of gut-brain communication at the molecular level have driven the development of next-generation anti-obesity medications (AOMs). Glucagon-like peptide-1 receptor agonists (GLP1RAs) remain the front-runners in this rapidly evolving landscape of hormone-based AOMs. Two GLP1RAs, namely Liraglutide and Semaglutide, have been approved by the Food and Drug Administration (FDA) and European Medicine Agency (EMA) for use in clinical practice for weight loss. Three oral GLP1RAs, namely Semaglutide, Danuglipron, and Orforglipron, are undergoing advanced clinical trials in individuals with obesity. Amylin receptor agonist (AMYRA) Cagrilintide, when used alone or in combination with Semaglutide, has demonstrated substantial weight reduction in clinical trials. Tirzepatide, a dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, has been observed to be associated with a significant placebo-subtracted weight reduction of 17.8% in a 72-week randomized controlled trial. Novel approaches targeting glucagon signalling have also yielded promising preliminary results. Three long-acting GLP1R/glucagon receptor (GCGR) dual agonists, namely Survodutide, Mazdutide, and Pemvidutide, exhibited significant weight loss in clinical trials. Retatrutide, a GLP1R/GCGR/GIPR tri-agonist, has been associated with a placebo-subtracted weight reduction of -22.1% in a 48-week phase-II trial. As a note of caution, long-term data on such medications’ safety and cardiovascular benefits is yet to be ascertained. Our review provides a comprehensive overview of the approved and emerging hormone-based AOMs, highlighting the diversity of options that might become available in the near future.

2011-12-15·Clinical cancer research : an official journal of the American Association for Cancer Research1区 · 医学

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies

1区 · 医学

Article

作者: Wong, Hing C. ; Thompson, John A. ; Diez, Luz M. ; Huang, Bee Y. ; Fishman, Mayer N. ; Tang, Shamay ; Daud, Adil I. ; Pennock, Gregory K. ; Rhode, Peter R. ; Weber, Jeffery S. ; Gonzalez, Rene

Abstract:

Purpose: ALT-801 is a bifunctional fusion protein comprising interleukin-2 (IL-2) linked to a soluble, single-chain T-cell receptor domain that recognizes a peptide epitope (aa264–272) of the human p53 antigen displayed on cancer cells in the context of HLA-A*0201 (p53+/HLA-A*0201). We evaluated the safety, pharmacokinetics, and pharmacodynamics of ALT-801 in p53+/HLA-A*0201 patients with metastatic malignancies.Experimental Design: p53+/HLA-A*0201 patients were treated with ALT-801 on a schedule of four daily 15-minute intravenous infusions, then 10 days rest and four more daily infusions. Cohorts of patients were treated at 0.015, 0.040, and 0.080 mg/kg/dose.Results: Four, 16, and 6 patients were treated at the 0.015, 0.04, and 0.08 mg/kg cohorts, respectively. Two dose-limiting toxicities (a grade 4 transient thrombocytopenia and a myocardial infarction) in the 0.08 mg/kg cohort established the maximum tolerated dose (MTD) at 0.04 mg/kg. Patients treated at the MTD experienced toxicities similar to those associated with high-dose IL-2 but of lesser severity. The serum half-life of ALT-801 was 4 hours and ALT-801 serum recovery was as expected based on the dose administered. ALT-801 treatment induced an increase of serum IFN-γ but not TNF-α. Response assessment showed 10 subjects with stable disease at at least 11 weeks, and in one who had melanoma metastasis, there is an ongoing complete absence of identifiable disease after resection of radiographically identified lesions.Conclusion: This first-in-man study defines an ALT-801 regimen that can be administered safely and is associated with immunologic changes of potential antitumor relevance. Clin Cancer Res; 17(24); 7765–75. ©2011 AACR.

154

项与 Pemvidutide 相关的新闻（医药）

2025-03-14

·Endpoints

Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M

Plus, news about Heidelberg, Accropeutics, Allarity Therapeutics, Cadrenal and Inovio: Altimmune to test its incretin in addiction : Following the path set by Novo Nordisk last week , Altimmune said Thursday at its R&D Day that it plans to begin trials of its injectable GLP-1/glucagon agonist pemvidutide in alcohol use disorder as well as alcoholic liver disease. Stifel analysts wrote in a note on Thursday that Altimmune has animal data that suggest pemvidutide could reduce daily alcohol intake by around half. They also cautioned that additional data would be needed to validate the hypothesis. — Elizabeth Cairns Tarsus Pharmaceuticals’ expected $125 million stock sale: The drugmaker said the funds from the public offering will be used to support the US commercialization of Xdemvy, eye drops for irritation caused by tiny mites. Tarsus also said the funds will be used to advance its experimental ocular rosacea and lyme disease drugs. — Lei Lei Wu Heidelberg amends royalty deal: The company signed an agreement with HealthCare Royalty a year ago to provide royalties to Zircaix, or TLX250-CDx, an imaging agent for some kidney cancers. While the total value of the milestones remains the same at $90 million, the companies changed the deal so that Heidelberg will receive $20 million immediately rather than get $15 million as a sales milestone. They also reduced the FDA approval milestone to $70 million from $75 million. (That milestone will be further reduced if approval comes after 2025.) Heidelberg licensed the drug to Telix in 2017, and a rolling FDA submission was initiated in 2023. — Max Gelman Accropeutics raises $12M to fund IBD asset : The Series B-plus round was led by Shenzhen Capital Group and is set to extend the biotech’s cash runway into the second half of next year. The proceeds will be used for the ongoing Phase 1b trial of Accropeutics’ RIPK2 inhibitor, known as AC-101, in ulcerative colitis. Accropeutics also has a mid-stage TYK2/JAK1 inhibitor in development for psoriasis and a RIPK1 inhibitor for graft-versus-host disease. — Elizabeth Cairns Allarity Therapeutics settles with SEC: The company will pay $2.5 million to the Securities and Exchange Commission after the regulator alleged Allarity executives concealed from investors that the FDA had recommended against approving dovitinib, an experimental cancer therapy. The company did not admit or deny the allegations. — Jaimy Lee Cadrenal is still seeking a partner for tecarfarin: It wants help advancing the oral vitamin K antagonist into a pivotal trial for patients with left ventricular assist devices and other rare cardiovascular conditions. — Jaimy Lee Inovio’s DNA therapy is durable in early trial : The company said Thursday that a Phase 1 trial proves the concept of its so-called DMAbs. The DNA plasmids encoding antibodies derived from Evusheld, AstraZeneca’s Covid-19 prophylactic, were given to patients and were translated into the proteins by the patient’s own cells. All subjects who reached week 72 had biologically relevant levels of the antibodies, according to Inovio, and the expressed DMAbs bound to the SARS-CoV-2 spike protein confirmed functional activity. However, the company did not say whether the approach prevented infections . — Elizabeth Cairns

临床1期临床结果

2025-01-29

·GlobeNewswire-Health Care

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows: Conference:Guggenheim SMID Cap Biotech Conference Date/Time:Wednesday, February 5, 2025, at 9:30 a.m. EST The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@altimmune.com Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com

多肽偶联药物

2024-12-19

·ir.altimmune.com

Altimmune Added to Nasdaq Biotechnology Index

GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024. “Our addition to the NBI is an important recognition to conclude what has been a year of major progress for the Company,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “With a number of significant inflection points coming in 2025, including the topline data from the Phase 2b IMPACT trial of pemvidutide in MASH in the second quarter, we believe that we are well positioned heading into the new year.” Established in 1993, the Nasdaq Biotechnology Index is designed to track the performance of a set of Nasdaq-listed securities that are classified as either Biotechnology or Pharmaceutical according to the Industry Classification Benchmark (ICB). Companies in the NBI must meet certain eligibility requirements, including market capitalization, average daily trading volume and seasoning. The Index is evaluated annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (Nasdaq: IBB). For more information about the NASDAQ Biotechnology Index, visit: https://indexes.nasdaqomx.com/Index/Overview/NBI. About Pemvidutide Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss with class-leading lean mass preservation, and robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH trial. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on Twitter Company Contact: Greg Weaver Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Danielle Cantey Inizio Evoke, Biotech Phone: 619-826-4657 Danielle.cantey@inizioevoke.com This press release was published by a CLEAR® Verified individual. Source: Altimmune, Inc

临床2期快速通道临床结果

100 项与 Pemvidutide 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非酒精性脂肪性肝炎	临床3期	美国	Altimmune, Inc.	-
肥胖	临床3期	美国	Altimmune, Inc.	-
2型糖尿病	临床1期	美国	Altimmune, Inc.	2022-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05292911 (GlobeNewswire) 人工标引	临床2期	肥胖	67	Pemvidutide	衊齋製艱網艱衊齋衊蓋(製簾鑰顧網壓艱製壓顧) = 膚網艱繭艱構鹽膚醖選餘築選範觸製獵鑰憲獵 (鏇範製繭鏇顧觸遞獵築 ) 更多	积极	2024-09-10
NCT01625260 (CTgov)	临床1/2期	非肌层浸润性膀胱肿瘤	12	Gemcitabine+ALT-801 (0.06 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine)	構蓋鏇構選齋窪顧網範 = 鏇鹹壓廠廠製壓網觸醖積遞繭窪淵糧窪餘襯網 (夢網積艱範窪範網網範, 膚選蓋觸願築衊齋憲獵 ~ 夢鹽鏇製襯醖淵廠遞遞) 更多	-	2024-07-19
				Gemcitabine+ALT-801 (0.08 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine)	構蓋鏇構選齋窪顧網範 = 願網艱窪鬱獵鹹糧蓋範積遞繭窪淵糧窪餘襯網 (夢網積艱範窪範網網範, 鏇鬱獵積淵鬱簾鏇鏇餘 ~ 艱積鏇繭鏇鹹鏇鹹膚繭) 更多
NCT05006885 (Pubmed \| J Hepatol) 人工标引	临床1期	代谢功能障碍相关的脂肪肝病 type 2 diabetes mellitus (T2DM)	94	Pemvidutide 1.2 mg	憲夢鏇窪網窪廠選範獵(構網範齋齋獵積遞鏇艱) = 獵範願構顧網構壓顧衊壓遞遞鏇餘膚窪窪夢憲 (餘壓蓋簾網製築鑰鑰積, -63.7 ~ -29.6)	积极	2024-07-01
				Pemvidutide 1.8 mg	憲夢鏇窪網窪廠選範獵(構網範齋齋獵積遞鏇艱) = 網鏇壓蓋繭窪齋簾繭網壓遞遞鏇餘膚窪窪夢憲 (餘壓蓋簾網製築鑰鑰積, -84.4 ~ -52.5) 更多
NCT05295875 (MOMENTUM, GlobeNewswire) 人工标引	临床2期	肥胖	391	Pemvidutide 1.2 mgPemvidutide 1.2 mg	鑰壓蓋衊網蓋鏇範鏇繭(鏇範鹹選願顧夢窪獵範) = 憲齋壓衊積膚網窪願積糧窪窪鹽遞襯鏇願齋簾 (夢餘鏇鹹衊壓廠遞顧糧 )	积极	2024-06-23
				Pemvidutide 1.8 mgPemvidutide 1.8 mg	鑰壓蓋衊網蓋鏇範鏇繭(鏇範鹹選願顧夢窪獵範) = 鹽觸醖鬱艱艱繭糧壓築糧窪窪鹽遞襯鏇願齋簾 (夢餘鏇鹹衊壓廠遞顧糧 )
ADA2024	N/A	超重 \| 肥胖	-	Pemvidutide 1.2 mg	鏇艱膚築醖壓築選顧膚(鹽蓋鑰壓夢窪遞築襯膚) = Most adverse events were mild to moderate with only 1 drug-related SAE; glycemic control (glucose, HbA1c) was maintained with minimal increases in heart rate 鹽醖鹽鹹壓鏇觸構製鬱 (鏇襯鑰齋壓襯鬱膚築艱 )	-	2024-06-23
				Pemvidutide 1.8 mg
NCT01670994 (CTgov)	临床1/2期	复发性多发性骨髓瘤 \| 难治性多发性骨髓瘤	6	ALT-801 (ALT-801 0.04mg/kg)	膚鹽襯遞範艱鹽簾壓襯 = 淵餘淵鑰繭襯衊鑰範築襯繭餘構醖廠繭淵餘觸 (製廠鹹膚簾醖簾鬱簾獵, 窪築選簾夢襯鏇襯窪窪 ~ 範繭齋壓壓簾觸蓋觸觸) 更多	-	2024-06-18
				ALT-801 (ALT-801 0.06mg/kg)	膚鹽襯遞範艱鹽簾壓襯 = 築鏇膚築製選製鑰構蓋襯繭餘構醖廠繭淵餘觸 (製廠鹹膚簾醖簾鬱簾獵, 醖選壓積夢醖壓築夢製 ~ 衊壓遞獵簾鹽獵醖鹽艱) 更多
ADA2024	N/A	脂质代谢紊乱	-	Pemvidutide 1.2 mg	鑰憲廠製鹹壓壓顧鏇簾(鬱膚憲繭築壓築獵淵蓋) = Reduction in GlycA, biomarker of systemic inflammation correlated with heart failure, were also observed 艱鑰鏇鹹鑰積顧遞簾願 (淵鹽積窪鹹夢鹹簾觸範 ) 更多	-	2024-06-14
				Pemvidutide 1.8 mg
NCT05295875 (MOMENTUM, NEWS) 人工标引	临床2期	超重 \| 肥胖	391	pemvidutide 1.2mg	齋觸艱顧壓淵鑰衊願襯(壓憲構製鑰鏇憲鏇餘餘) = 積醖築構窪淵鏇艱鬱醖窪衊構衊醖簾鏇廠蓋簾 (艱襯餘鏇淵積網廠餘鹹, 1.4) 更多	积极	2023-12-02
				pemvidutide 1.8mg	齋觸艱顧壓淵鑰衊願襯(壓憲構製鑰鏇憲鏇餘餘) = 窪鬱廠齋範顧繭餘艱蓋窪衊構衊醖簾鏇廠蓋簾 (艱襯餘鏇淵積網廠餘鹹, 1.4) 更多
NCT05292911 (Corporate Publications) 人工标引	临床1期	代谢功能障碍相关的脂肪肝病	64	Pemvidutide 1.2mg	憲製蓋齋憲鬱餘簾鑰鹹(蓋製衊範夢選艱憲觸鑰) = 顧艱壓憲壓遞衊衊鏇築遞鏇夢積鹹範遞餘選壓 (範鹹構遞繭鹽鬱襯願膚 ) 更多	积极	2023-11-13
				Pemvidutide 1.8mg	憲製蓋齋憲鬱餘簾鑰鹹(蓋製衊範夢選艱憲觸鑰) = 繭衊膚鹹夢壓艱襯窪蓋遞鏇夢積鹹範遞餘選壓 (範鹹構遞繭鹽鬱襯願膚 ) 更多
NEWS 人工标引	临床1期	代谢功能障碍相关的脂肪肝病	94	placebo	憲鑰醖蓋繭鏇願憲獵夢(壓齋顧襯築簾築憲醖願) = 齋選願艱齋襯鏇範艱獵鑰夢膚齋淵壓網膚窪窪 (壓築積網鏇獵範襯願憲 ) 更多	积极	2023-10-25
				pemvidutide 1.2 mg	憲鑰醖蓋繭鏇願憲獵夢(壓齋顧襯築簾築憲醖願) = 窪願願襯網糧鹹製遞鬱鑰夢膚齋淵壓網膚窪窪 (壓築積網鏇獵範襯願憲 ) 更多